Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review | Zendy

Daniel Caldeira | Zendy; Hélder Pereira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review

Author(s) -

Daniel Caldeira,

Hélder Pereira

Publication year - 2019

Publication title -

revista portuguesa de cardiologia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.266

H-Index - 26

eISSN - 2174-2030

pISSN - 0870-2551

DOI - 10.1016/j.repc.2018.05.020

Subject(s) - tirofiban , cangrelor , medicine , abciximab , prasugrel , clopidogrel , eptifibatide , bivalirudin , ticagrelor , percutaneous coronary intervention , aspirin , p2y12 , dabigatran , myocardial infarction , low molecular weight heparin , pharmacology , heparin , warfarin , atrial fibrillation

This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention. These drugs include oral antiplatelets (aspirin and P2Y 12 inhibitors such as clopidogrel, prasugrel and ticagrelor), intravenous antiplatelet agents (the P2Y 12 inhibitor cangrelor, GP IIb/IIIa inhibitors such as abciximab, eptifibatide and tirofiban), and intravenous anticoagulant agents (unfractionated heparin, low molecular weight heparin and bivalirudin).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research